Xiangyu Medical Co.,Ltd (SHA:688626)
China · Delayed Price · Currency is CNY 68.28
+1.52 (2.28%)
At close: Feb 13, 2026
Xiangyu Medical Co.,Ltd Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 764.03 | 733.63 | 736.61 | 483.87 | 515.8 | 491.24 |
Other Revenue | 9.9 | 9.9 | 8.2 | 4.66 | 7.7 | 4.27 |
| 773.93 | 743.53 | 744.81 | 488.53 | 523.5 | 495.51 | |
Revenue Growth (YoY) | 9.07% | -0.17% | 52.46% | -6.68% | 5.65% | 15.93% |
Cost of Revenue | 260.9 | 252.61 | 243.35 | 170.08 | 169.57 | 162.69 |
Gross Profit | 513.03 | 490.92 | 501.46 | 318.44 | 353.92 | 332.82 |
Selling, General & Admin | 310.77 | 274.02 | 210.41 | 175.89 | 140.42 | 113.99 |
Research & Development | 173.38 | 152.02 | 106.75 | 92.41 | 68.61 | 51.55 |
Other Operating Expenses | -10.82 | -7.41 | -9 | -3.6 | 0.55 | 2.88 |
Operating Expenses | 476.02 | 421.82 | 310.31 | 264.77 | 211.78 | 170.12 |
Operating Income | 37.01 | 69.09 | 191.15 | 53.67 | 142.15 | 162.7 |
Interest Expense | -6.53 | -3.63 | -2.66 | -0.19 | - | -0.17 |
Interest & Investment Income | 30.04 | 26.6 | 38.82 | 37.59 | 33.73 | 11.64 |
Currency Exchange Gain (Loss) | 0.07 | 0.07 | 0.02 | 0.02 | -0.02 | 0.06 |
Other Non Operating Income (Expenses) | -1.72 | 1.04 | 2.39 | 2.61 | 2.16 | 1.1 |
EBT Excluding Unusual Items | 58.87 | 93.17 | 229.72 | 93.7 | 178.02 | 175.33 |
Gain (Loss) on Sale of Investments | - | - | -3.24 | -1.06 | - | -0.31 |
Gain (Loss) on Sale of Assets | 0.08 | 0.07 | 0.01 | - | -0.01 | 0.01 |
Asset Writedown | -0.65 | -0.05 | -0.02 | -0.25 | - | -0.14 |
Other Unusual Items | 14.04 | 14.04 | 17.55 | 40.6 | 44.72 | 47.9 |
Pretax Income | 72.34 | 107.24 | 244.03 | 132.99 | 222.72 | 222.79 |
Income Tax Expense | 0.96 | 4.38 | 15.72 | 9.7 | 23.18 | 26.78 |
Earnings From Continuing Operations | 71.38 | 102.85 | 228.31 | 123.3 | 199.54 | 196.01 |
Minority Interest in Earnings | 2.13 | 0.09 | -1.17 | 2.17 | 2.36 | 0.25 |
Net Income | 73.51 | 102.94 | 227.14 | 125.47 | 201.9 | 196.26 |
Net Income to Common | 73.51 | 102.94 | 227.14 | 125.47 | 201.9 | 196.26 |
Net Income Growth | -39.44% | -54.68% | 81.03% | -37.85% | 2.87% | 52.17% |
Shares Outstanding (Basic) | 153 | 156 | 158 | 159 | 150 | 120 |
Shares Outstanding (Diluted) | 153 | 156 | 158 | 159 | 150 | 120 |
Shares Change (YoY) | -2.83% | -1.12% | -0.68% | 6.20% | 24.97% | -0.72% |
EPS (Basic) | 0.48 | 0.66 | 1.44 | 0.79 | 1.35 | 1.64 |
EPS (Diluted) | 0.48 | 0.66 | 1.44 | 0.79 | 1.35 | 1.64 |
EPS Growth | -37.68% | -54.17% | 82.28% | -41.48% | -17.68% | 53.27% |
Free Cash Flow | -181.16 | -260.3 | -251.35 | -16.37 | 31.97 | 76.69 |
Free Cash Flow Per Share | -1.19 | -1.67 | -1.59 | -0.10 | 0.21 | 0.64 |
Dividend Per Share | 0.240 | 0.240 | 0.530 | 0.240 | 0.380 | 0.370 |
Dividend Growth | -54.73% | -54.73% | 120.90% | -36.84% | 2.70% | - |
Gross Margin | 66.29% | 66.03% | 67.33% | 65.18% | 67.61% | 67.17% |
Operating Margin | 4.78% | 9.29% | 25.66% | 10.99% | 27.15% | 32.84% |
Profit Margin | 9.50% | 13.84% | 30.50% | 25.68% | 38.57% | 39.61% |
Free Cash Flow Margin | -23.41% | -35.01% | -33.75% | -3.35% | 6.11% | 15.48% |
EBITDA | 87.09 | 105.17 | 208.57 | 69.74 | 153.52 | 173.48 |
EBITDA Margin | 11.25% | 14.14% | 28.00% | 14.27% | 29.33% | 35.01% |
D&A For EBITDA | 50.08 | 36.08 | 17.41 | 16.06 | 11.37 | 10.78 |
EBIT | 37.01 | 69.09 | 191.15 | 53.67 | 142.15 | 162.7 |
EBIT Margin | 4.78% | 9.29% | 25.66% | 10.99% | 27.15% | 32.84% |
Effective Tax Rate | 1.32% | 4.09% | 6.44% | 7.29% | 10.41% | 12.02% |
Revenue as Reported | 773.93 | 743.53 | 744.81 | 488.53 | 523.5 | 495.51 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.